Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab

NCT01867294 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Academic and Community Cancer Research United

Collaborators